IMUC ImmunoCellular Therapeutics Ltd.

INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against ImmunoCellular Therapeutics, Ltd.

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC). Investors who purchased the Company’s shares between May 1, 2012 and December 11, 2013 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the June 30, 2017 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate.

In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.goldberglawpc.com/, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Complaint alleges that during the Class Period, ImmunoCellular violated federal securities laws by making materially false and misleading public statements. In September 2011, ImmunoCellular hired Lidingo Holdings, LLC, a stock promotional firm, to inflate the value of the Company’s shares. As a result, investors were led to believe that the Company’s clinical studies for its lead product candidate, ICT-107, were going well. On December 11, 2013, ImmunoCellular announced that the primary endpoint for its ICT-107 Phase II study “did not reach statistical significance” because it failed to increase overall survival in patients diagnosed with glioblastoma multiforme. When this news was announced, ImmunoCellular’s stock price dropped materially, causing investors harm. On April 10, 2017, as part of a U.S. Securities & Exchange Commission proceeding, the Company’s former CEO Manish Singh acknowledged participating “in a paid stock-touting scheme.”

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
03/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ImmunoCellular Therapeutics Ltd.

 PRESS RELEASE

ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivati...

ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivative Action LOS ANGELES, Aug. 09, 2019 (GLOBE NEWSWIRE) -- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC), today issued the following announcement. The following is being released pursuant to an Order of the Superior Court of California, County of Los Angeles, entered on August 2, 2019, in the matter of: DAVID WIENER, derivatively and on behalf of IMMUNOCELLULAR THERAPEUTICS, LTD. v. FRACTOR et al., Case No. BC670134 NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO:               ALL OWNERS OF IM...

 PRESS RELEASE

The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf...

NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunoCellular Therapeutics, Ltd. (NYSEMKT: IMUC) who purchased shares between May 1, 2012 and December 11, 2013. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misle...

 PRESS RELEASE

The Klein Law Firm Notifies Investors of a Class Action Filed on Behal...

NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunoCellular Therapeutics, Ltd. (NYSEMKT: IMUC) who purchased shares between May 1, 2012 and December 11, 2013. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misle...

 PRESS RELEASE

IMMUNOCELLULAR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Su...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSEMKT:IMUC) of the June 30, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in ImmunoCellular stock or options between May 1, 2012 and December 11, 2013 and would like to discuss your legal rights, click here: www.faruqilaw.com/IMUC. There is no...

 PRESS RELEASE

IMUC SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Invest...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics") (NYSEMKT: IMUC) securities between May 1, 2012 and December 11, 2013. Click here to learn about the case: http://www.wongesq.com/pslra-sa/immunocellular-therapeutics-ltd?wire=2. There is no cost or obligation to you. Acco...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch